OncoMatch/Clinical Trials/NCT05911217
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
Official title: An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic Cancer
Is NCT05911217 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies CT041 autologous CAR T-cell for pancreatic cancer.
Treatment: CT041 autologous CAR T-cell — An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: CLDN18 expression (positive)
Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: adjuvant chemotherapy — postoperative pancreatic cancer
had received months of standard adjuvant therapy
Cannot have received: neoadjuvant therapy for pancreatic cancer
Prior neoadjuvant therapy for pancreatic cancer
Cannot have received: gene-modified cell therapies (including CAR T, TCR T)
Previously received any gene-modified cell therapies (including CAR T, TCR T)
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05911217 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant therapy for pancreatic cancer, gene-modified cell therapies (including CAR T, TCR T) disqualifies patients from enrollment.
Does this trial require CLDN18?
Yes, CLDN18 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 79 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages